Brief: Avalyn Announces Additional Long-Term Data On Ap01, Inhaled Pirfenidone, For The Treatment Of Pulmonary Fibrosis
21/05/2026 13:38
May 21 (Reuters) - Avalyn Pharma Inc AVLN.O: AVALYN ANNOUNCES ADDITIONAL LONG-TERM DATA ON AP01, INHALED PIRFENIDONE, FOR THE TREATMENT OF PULMONARY FIBROSIS TO BE PRESENTED AT THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY 2026 Source text: ID:nGNX4dtJxx Further company coverage: AVLN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avalyn Pharma
See all newsU.S. RESEARCH ROUNDUP-Broadcom, CrowdStrike, Home Depot
U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy
U.S. RESEARCH ROUNDUP- Analog Devices, Crowdstrike, Deere & Co
Brief: Avalyn Announces Additional Long-Term Data On Ap01, Inhaled Pirfenidone, For The Treatment Of Pulmonary Fibrosis
NASDAQ RESUMED AT 12:23 PM